معرفی
Dr. Jeanette Lundin is a Senior Lecturer affiliated with the Department of Oncology-Pathology at Karolinska Institutet. Her research focuses on Precision Medicine in Lymphoid Malignancies, particularly Chronic Lymphocytic Leukemia (CLL), spanning clinical trials, immunotherapy, and tumor microenvironment studies.
- Doctor of Philosophy (2003), Karolinska Institutet
- Docent (2010), Karolinska Institutet
Research Interests
Lundin's work in CLL involves:
- Developing monoclonal antibody therapies (e.g., alemtuzumab, rituximab)
- Investigating tyrosine kinase receptor signaling (e.g., ROR1 phosphorylation)
- Optimizing drug combinations (e.g., ibrutinib, lenalidomide)
- Assessing immune reconstitution during therapy
- Evaluating real-world treatment outcomes in Swedish cohorts
Key Research Trends
Her publications highlight:
- Phase I/II clinical trials in high-risk CLL
- Complement activity assays for therapeutic monitoring
- Long-term safety profiles of alemtuzumab and fludarabine
- Viral reactivation risks in immunosuppressed patients
- Ibrutinib's impact on inflammatory markers and gene expression
Labs & Collaborations
She is part of the Anders Österborg's Group, contributing to translational research in lymphoid malignancies and immune-oncology.
۰مقاله منتشرشده
